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The molecular instructions that govern gene expression regulation are encoded in the genome and ultimately determine the
morphology and functional speciﬁcations of the human brain. As a consequence, changes in gene expression levels might be
directlyrelatedtothefunctionaldeclineassociatedwithbrainaging.SmallnoncodingRNAs,includingmiRNAs,compriseagroup
of regulatory molecules that modulate the expression of hundred of genes which play important roles in brain metabolism. Recent
comparative studies in humans and nonhuman primates revealed that miRNAs regulate multiple pathways and interconnected
signaling cascades that are the basis for the cognitive decline and neurodegenerative disorders during aging. Identifying the roles
of miRNAs and their target genes in model organisms combined with system-level studies of the brain would provide more
comprehensive understanding of the molecular basis of brain deterioration during the aging process.
1. The Aging Proﬁle of the Human and
Nonhuman PrimateBrain
The molecular and structural transformations that shape the
human cognitive abilities occur mostly in the period be-
tween birth and adulthood although some developmental
processes,suchascorticalaxonmyelinization,extendbeyond
this time window [1–3]. The primate brain is subjected to
dramatic change, both structurally and functionally, during
postnatal development [1, 4]. It is quite remarkable that the
process of brain aging begins at early adulthood that is man-
ifested by gradual deterioration of the brain capacity to
utilize the ﬂow of information. In later life, the brain begins
to change in a more destructive manner. Such changes in-
clude a decrease in brain volume, loss of synapses, cognitive
decline, and a rise in the frequency of neurological disorders
[2, 5–7]. Although developmental and aging-related changes
are clearly observed histologically and in cognitive function,
their molecular underpinnings are still poorly understood.
Multiple cellular and functional transformations take
place in the brain during aging. Neural cells may respond to
these changes by reprogramming metabolic circuits in order
to adapt and maintain its functionality, or they may give in
to neurodegenerative cascades that result in disorders such
as Alzheimer’s, cerebellar ataxias, and Parkinson’s diseases.
A number of mechanisms are employed to maintain the
integrity of nerve cell networks and to facilitate responses
to external and internal environmental stimuli and maintain
neuron integrity and functional capability after damage. The
protective machinery includes production of neurotrophic
factors and cytokines, expression of various cell survival-
promoting proteins (e.g., antioxidant factors, prosurvival
and antiapoptotic proteins, and protein chaperones), activa-
tion of DNA caretaker cascades to preserve the genomic in-
tegrity, and mobilization of neural stem cells to replace
damaged neurons and glial cells. The aging process presents
a challenge for the neuroprotective and neurorestorative
mechanisms. Genetic background and environmental stress-
ors superimposed upon the aging dynamic are the deter-
mining factors of the physiological versus pathological brain
aging. The importance of genetic predisposition to accel-
erated aging and neurodegeneration is well documented.2 Current Gerontology and Geriatrics Research
The accumulation of toxic proteins transcribed from mutat-
edgenescausesinheritedformsofAlzheimer’sdisease(amyl-
oid precursor protein and presenilins), Parkinson’s disease
(α-synuclein and Parkin), and trinucleotide repeat disorders
(huntingtin, androgen receptor, ataxin, and others) by
overcoming the endogenous neuroprotective mechanisms.
The neuroprotective mechanisms can be augmented by
dietary and behavioral modiﬁcations, such as caloric restric-
tion, antioxidant supplements, and physical activities. Also,
activating a response in which neurons increase production
of neurotrophic factors and stress proteins can facilitate
physiologically adequate brain aging. Neural stem cells that
reside in the adult brain are also responsive to environmental
demands and appear capable of replacing lost or dysfunc-
tional neurons and glial cells revealing a remarkable capacity
within brain cells for adaptation to aging and resistance to
disease.
Although rodent models to study brain aging and neuro-
degenerative disorders have been developed, these models do
not satisfactorily parallel the brain changes and behavioural
featuresobserved in humans. The close physiological, neuro-
logical, and genetic similarities between humans and higher
primatesoﬀertheopportunitytostudytheagingprocessand
associated abnormalities in monkeys [8, 9]. Aged nonhuman
primates undergo age-associated structural and functional
brain changes similar to those that occur in aged humans
and, to some degree, in individuals with Alzheimer’s disease
[9]. As in humans, declines in performance on cognitive and
memory tasks begin at the monkey equivalent of late-middle
life. The brains of old monkeys show degenerative changes in
neurons, abnormal axons and neurites, and accumulations
of amyloid plaques and lipofuscin around blood vessels
and in the residential macrophages [8]. Moreover, old non-
human primates exhibit decline of speciﬁc neurotransmitter
networks, most notably the forebrain cholinergic system
that has been suggested to contribute to the memory deﬁcit
characteristic for older individuals.
2.BrainAging andMicroRNA
Expression Proﬁles
Genome-wide gene expression studies during ageing of
the nematode Caenorhabditis elegans, the common fruit
ﬂy (Drosophila melanogaster), and the brains of mice, rats,
chimpanzees, and humans have revealed a few broadly con-
served functional categories of genes with age-dependent ex-
pression changes [17–23].In particular, most of these studies
provided evidence of reduced mitochondrial function and
increased expression of stress-response genes during aging
that were even more pronounced in humans with cognitive
decline and neurodegenerative disorders [24]. Thus, it ap-
pears that some conserved mechanisms of stress resistance
are activated during the brain aging to protect against the
pathology of neurodegenerative disorders. However, despite
clear evidence of conservation of ageing pathways and gene
expression signatures, the direct comparison of gene expres-
sion during ageing in mouse, rhesus macaque, and human
brain has revealed a major evolutionary divergence [19].
Factors such as DNA methylation, histone modiﬁcation,
chromatin remodeling, and small noncoding RNAs can
all contribute to the broad variety of phenotypes of age-
ing. Among these, the group of small noncoding RNAs call-
ed microRNAs (miRNAs) have been recently found to have
signiﬁcant impact on brain aging as well as cellular senes-
cence [25–27]. In the past decade, the accumulated knowl-
edge of small noncoding RNAs (ncRNAs) has provided new
understanding in the spatiotemporal regulation of gene ex-
pression. The category of small noncoding regulatory RNAs
include miRNAs, small interfering RNAs (siRNAs), PIWI-
interacting RNAs (piRNAs), small nucleolar RNAs (snoR-
NAs), and small nuclear RNAs (snRNAs). Thus far, the best
studied small ncRNAs are the microRNAs (miRNAs), a large
group of short (18–25 nucleotide), noncoding RNA mole-
cules transcribed either by RNA polymerase II or RNA poly-
merase III. Most miRNA-mediated regulation occurs at the
posttranslational level, primarily through its near-perfect
or partial complementary to consensus elements within 3 -
untranslated region (3  UTR) of target mRNA, leading to
translational repression and/or degradation. In some cases,
they may also promote translation [28, 29]( P e r s e n g i e v ,u n -
published data).
miRNAs play an important role in the regulation of sev-
eral cell processes, including cell proliferation, development,
cancer formation, stress responses, and apoptosis. The rapid
progression of miRNA research in these areas has revealed its
prominent role in modulating gene expression. However, the
role of miRNAs in senescence remains poorly understood.
miRNA can aﬀect pathways involved in ageing, and miRNA
proﬁling has shown signiﬁcant alterations in their expression
level. Importantly, recent data have shown the signiﬁcance
of miRNA in brain aging and neurodegeneration [26, 27,
30, 31]. The genome-wide expression analysis of miRNAs
in aging individuals revealed a general decline in miRNA
levelsthatwaslinkedtopotentiallossofcontrolofcancer-as-
sociated genes [32]. Nine miRNAs (miR-103, miR-107, miR-
128, miR-130a, mIR-155, miR-24, miR-221, miR-496, and
mIR-1538) were identiﬁed to be signiﬁcantly lower in the
peripheral blood mononuclear cells of old individuals as
compared to the young subjects that were identiﬁed in this
study.
Identifying the regulatory circuitry processes that control
cell diﬀerentiation and transmission of information between
neurons is fundamental to understanding changes in the
aging brain. miRNAs regulate expression of protein-coding
genes[33,34].SeverallinesofevidenceindicatethatmiRNAs
contribute to the control of brain development and its func-
tional and structural reorganization, as a result of age pro-
gression and deterioration of neuronal metabolism. A subset
of miRNAs is selectively expressed in brain tissues [35], and
miRNA expression proﬁling in the adult brain of diﬀerent
species separated the human brain regions from those of
chimpanzee, mouse, and rat [19, 36, 37]. Moreover, targeted
inactivation of Dicer miRNA processing endonuclease was
found to lead to degeneration of Purkinje cells [34]a n d
retinal cells deﬁcient for Dicer undergoes a progressive
degeneration [33]. Speciﬁc miRNAs have been shown and
in some cases predicted with high conﬁdence to be involvedCurrent Gerontology and Geriatrics Research 3
Table 1: List of miRNAs that are reported or have high probability to inhibit the expression of genes linked to neurodegenerative disease
development.
Disease Risk gene miRNA References
Alzheimer’s disease A-beta miR-101 [10]
Parkinson’s disease α-synuclein miR-7, miR-153 [11]
Spinocerebellar ataxia type 1 (SCA1) Ataxin 1 miR-144, miR-107, miR-130, miR-19 [12, 13]
Amyotrophic lateral sclerosis (ALS) SOD1 miR-206 [14]
Spinocerebellar ataxia type 7 (SCA7) Ataxin 7 miR-199∗, miR-141∗, miR-200a∗ [15, 16]
Huntington’s disease Huntingtin miR-216∗, miR-107∗, miR-27ab∗, miR-128∗ [15, 16]
∗miRNAs that have high potential to inhibit ataxin 7 and Huntingtin gene expression as predicted by Target Scan (release 5.2).
in Alzheimer’s disease, spinocerebellar ataxia type 1, Parkin-
son’s disease, and amyotrophic lateral sclerosis (ALS), in
addition to the general dysregulation of miRNA expression
observed in neurodegenerative disorders [10–16, 26, 38–40]
(see Table 1 for details). However, how miRNA expression is
regulated during brain aging and how miRNAs participate
in the regulatory loops controlling brain function is not well
understood.
We recently performed a genome-wide expression screen
of miRNAs and ncRNAs in the brain of chimpanzees and
humans and found that miRNA expression is diﬀerentially
regulated in the cortex and cerebellum of humans and non-
humanprimatesduringaging.ThemiRNAlevelsremainrel-
atively stable in the cortex in contrast to the general miRNA
downregulation associated with the aging cerebellum. This
observation is signiﬁcant and apparently reﬂects the tempo-
ral functional status of neuronal activity in the cortex and
cerebellum. However, there was no unifying speciﬁc miRNA
pattern associated with the brain aging. Despite this observa-
tion, the group of targeted genes was remarkably conserved
during evolution especially when their role in biological
process regulation was used as criteria for the ontological
analysis (Figure 1). Interestingly, the data identiﬁed miR-144
to be the sole miRNA that was consistently upregulated in
the aging chimp and human cerebellum and cortex [13]. The
selective increase of miR-144 levels suggests that miR-144 is
likely to play a coordinating role in the posttranscriptional
r e g u l a t i o no fag r o u po fg e n e st h a ta r es u b j e c t e dt os t r o n g
miRNA control in the aging brain. This ﬁnding implies that
the onset of aging, responsiveness to environmental stress
signals, and the associated risk of disease development are
encoded within the genes themselves which in turn deter-
mines the individual gene expression proﬁles.
3.The AdaptiveRole of MicroRNAs
in Neurodegeneration
The brain is a complex organ, with various types of neu-
rons and nonneuronal cell types that form an intricate com-
munication network. Aging-related neurodegenerative dis-
eases are the culmination of many diﬀerent genetic and en-
vironmental inﬂuences. Prior studies have shown that RNA
regulation is altered during the course of some neurodegen-
erativedisorders.Recently,anumberofpaperssuggestedthat
miRNAs might be a contributing factor in neurodegener-
ation.TheexperimentaldatahaveshownthatmanymiRNAs
are expressed in speciﬁc brain regions, suggesting their
functional role in brain activities. For instance, miRNAs
have been implicated in neural cell developments, and miR-
128 was shown to reduce the expression of the neural stem
cell renewal factor Bmi-1 [41]. In the mammalian brain,
miR-9 and miR-132 are expressed in hippocampus and
medal frontal gyrus [26]. miR-9 expression is necessary for
neurogenesis in cultured stem cells and its downregulation
correlates with premature cortical diﬀerentiation in presen-
tiling-1 knockout mice [42]. miR-132 is an inhibitor of
p250GAP translation that plays a role in neurite extension
and neurogenesis [43]. In addition, miR-132 has been linked
to BDNF, a member of the nerve growth factor family that
is necessary for survival of striatal neurons in the brain,
and MeCP2 methyl-CpG DNA binding protein that plays
an essential role in mammalian development [44]. Another
miRNA, miR-124a, plays a role in the diﬀerentiation of neu-
ronal progenitors into mature neurons by controlling the
elimination on nonessential transcripts [45]. miR-9, miR-
132, and miR-124a expression is inhibited in nonneural cells
by the transcriptional repressor REST that helps to preserve
the identity of nervous tissue by silencing neuronal genes in
nonneural tissues [46].
Research about miRNAs in the context of neurodegener-
ation is accumulating rapidly, and recently published studies
suggested a role of miRNAs in Alzheimer’s disease, Parkin-
son’s disease, and triplet repeat disorders. In the cortex of
Alzheimer patients, the expression of miR-107 was reduced
signiﬁcantly even in patients with very early pathological
alterations [47]. miR-107 lowers the expression of b-site
amyloid precursor protein-cleaving enzyme 1 (BACE1) and
may be involved in the acceleration of Alzheimer’s disease
progression. Disruption of miR-433 binding site in ﬁbroblast
growth factor 20 (FGF20) 3  UTR correlates with increased
alfa-synuclein expression in Parkinson patients [48]. miR-
133b that is speciﬁcally expressed in the midbrain dopamin-
ergic neurons and functions to ﬁne-tune the dopaminergic
behaviours, such as locomotion, is deﬁcient in midbrain
tissues from Parkinson patients [49]. Thus, a connection be-
tween miRNA and ageing-associated neurodegenerative ab-
normalities is emerging and provides new insights into the
mechanisms of disease development.
miRNAs are generally considered to play defensive func-
tions at the level of the whole organism [27, 34, 50, 51]. We
observed a general induction of miRNA and ncRNA expres-
sion in the brain compartments of SCA1 and Alzheimer4 Current Gerontology and Geriatrics Research
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Figure 1: Expression of selected miRNAs is induced in the aging cerebellum and cortex of chimpanzees and humans. The asterisks indicate
groups of miRNAs and ncRNAs that are speciﬁcally upregulated in the aging human cerebellum and cortex. Ontology analysis for biological
function of the human upregulated miRNA target genes in the cerebellum and cortex of aged individuals is shown below the heatmaps.
patients (Figure 2). It is expected that downregulation of
miRNA expression during the progress of aging would lead
to a diminished control on posttranscriptional processing of
gene expression. The higher levels of processed miRNA and
ncRNA transcripts in the cerebellum and cortex diagnosed
with neurodegenerative disorders might be a compensatory
reaction to diminish the eﬀect of aberrant proteins buildup
in the aﬀected compartments. Two diﬀerent mechanisms
may account for this phenomenon: ﬁrst, miRNA response
might be directly or indirectly linked to the mutant protein
expression (e.g., ATXN1 in spinocerebellar ataxia type 1 and
APP in Alzheimer’s disease), or second, a result of a general
transcriptionalderegulationintheaﬀectedtissues.Theaging
brain retains the expression of small number of miRNAs
that are able to exercise a limited but adequate control on
gene expression and support neuron functioning. miRNA
expression is markedly increased in the brain of SCA1 and
Alzheimer patients that suggests that the trigger for the
miRNA response is the excessive amount of toxic metabolites
and is mainly directed to restrict their negative eﬀect.
However, it is worth considering that the overactivation of
m i R N Am a c h i n e r y ,a st h ep r o c e s so fn e u r o nd e g e n e r a t i o n
progresses, could have a negative impact on the neuron
function. Thus, a detailed understanding of the mechanisms
and factors involved in the miRNA processing in the brain
during normal aging and in aging-associated pathologies
that are manifested by progressive loss of function will
require further studies.Current Gerontology and Geriatrics Research 5
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Figure 2: Activation of miRNA expression in the aﬀected brain compartments of Alzheimer’s and SCA1 patients. The asterisks indicate the
subsets of miRNAs and ncRNAs that are speciﬁcally upregulated in SCA1 cerebellum and Alzheimer’s cortex.
A long-standing question in the ﬁeld of brain aging
and neurodegeneration is how the ubiquitous expression
of mutant proteins can be reconciled with their neuron-
speciﬁc cytotoxic eﬀect in deﬁned brain compartments. For
instance, it is well documented that the expanded poly-
glutamine proteins, such as ATXN1, are ubiquitously ex-
pressed,butthediseaseaﬀectsonlysubsetsofneurons.These
data suggest that the sensitivity of particular neuron popula-
tion to the mutant protein is facilitated by additional mech-
anism(s) and might incorporate the eﬀectiveness of miRNA
response. Thus, it is likely that the maintenance of selected
miRNA expression in the aging brain serves as a default
protective function, and the deregulation of this mechanism
contributes to neurodegenerative disorders.
4.Regulatory PathwaysModulatedby
MicroRNAs in the Brain
4.1. Apoptosis and Cell Survival Pathways. Recent research
has demonstrated that miRNAs are key regulators of cell
death mechanism acting either as inhibitors of apoptosis ac-
tivation or proapoptotic factors. Many miRNAs are antiapo-
ptotic and mediate this eﬀect by targeting pro-apoptotic
m R N A so rp o s i t i v er e g u l a t o r so fp r o - a p o p t o t i cm R N A s .O n
the other hand, pro-apoptotic miRNAs target anti-apoptotic
mRNAs or their positive regulators. For instance, miRNA
let-7 promotes tumorigenesis by regulation of KRAS and
NRAS transcripts [52]. miRNAs are known to regulate path-
ways controlled by genes such as p53, MYC, and RAS.
Furthermore, miR17-92 cluster has been shown to be able
to act as a functional switch between cell proliferation and
apoptosis. miRNAs have also been shown to be involved
in apoptosis. For example, some miRNAs (miR-497, miR-
128, miR-15, and miR-16) can induce apoptosis by targeting
BCL2 in neuronal cells [9, 53, 54]. miR-21 can reduce
apoptosis by targeting PDCD4 proapoptotic gene that has
been linked to Alzheimer’s disease [18, 32, 55]. Interestingly,
PDCD4 3  UTR also contains a conserved response element
for miR-144 suggesting that the aging-speciﬁc miR-144
might play a role in the inhibition of apoptosis by repressing
the activity of PDCD4. In addition, knockdown of Dicer
has been shown to result in increased cortical apoptosis and
causes neuronal dysfunction and degeneration [17, 56].
4.2. Cell Cycle Regulation. Cell cycle progression can be
halted by two separate but interacting pathways the p53 and
p16-pRb pathways. Our current knowledge remains sketchy
about the kind of damage that may cause a neuronal cell to
undergo apoptosis or senescence under diﬀerent stimuli. It is
likely that the eﬀect of intacellular and environmental factors
is both cell type as well as stimulation speciﬁc. The p53 path-
way mainly governs DNA damage response-induced sen-
escence. p21 is the critical downstream transcription target
of p53 and plays a key mediator role in regulating p53-in-
duced senescence. Several miRNAs modulate the expression
of p53, p21, or their downstream targets and as a conse-
quence regulate cellular senescence [53, 54, 57].
4.3. Neuroinﬂammatory Pathways. Most acute and chronic
neurodegenerative conditions are accompanied by neuroin-
ﬂammation, yet the exact nature of the inﬂammatory pro-
cesses and whether they are trigger or consequence of dis-
ease progression is not well understood. Various cellular
mechanismsassociatedwithneurodegenerationareactivated
or enhanced by inﬂammatory processes that may contribute
to mitochondrial dysfunction, oxidative stress, or apoptosis
of neurons. More recently, tumor necrosis factor (TNF)
and interleukin-1-beta (IL-1β) signaling pathways have been
found to play a role in the pathogenesis of Alzheimer’s and
Parkinson’s diseases [10, 55]. TNF signaling plays a key role
in mediating neuronal cell death, and TNF receptor deﬁ-
ciency appears to have a neuroprotective eﬀect [55]. IL-1β
overexpression has been implicated as factor in the initiation
and progression of Alzheimer’s disease [58]. Moreover, IL-
1β promotes APP transcription and translation in various
cell types [59–61]. miR-101 reduced APP expression after
prolonged IL-1β treatment, suggesting a role for miR-101 in
the control of APP expression in response to IL-1β in Alz-
heimer’s disease [10].6 Current Gerontology and Geriatrics Research
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Figure 3: Model depicting miRNAs regulatory networks in the brain compartments aﬀected by neurodegenerative disorders and the
potential protective feedback loops that operate during aging-induced functional deterioration.
4.4. Ubiquitin-Proteasome Pathway. The accumulation of
misfolded proteins is a recurring event during brain aging
and is exacerbated in several neurodegenerative diseases,
including SCA1 and Alzheimer’s diseases [62–64]. It has
been suggested that protein accumulation may result from
a dysfunction in the ubiquitin proteasome system (UPS). In-
deed, there is mounting genetic and biochemical evidence of
an involvement of the ubiquitin proteasome system in SCA1
[65, 66]. We have recently identiﬁed HECTD1 and RNF8 E3
ubiquitin-protein ligases as targets of ncRNA in the cortex
and cerebellum of individuals diagnosed with spinocerebel-
lar ataxia type 1 and Alzheimer’s disease (Persengiev et al.,
submitted). The HECT family of protein ligases ubiquitinate
proteins for degradation by the 26S proteosome protein
complex and have nonredundant functions in regulating
speciﬁc signaling cascades [67, 68]. As such, deregulation of
HECT ligases and the miRNAs that regulate their expression
can severely perturb neuronal structure and function and
may lead to functional collapse of the postmitotic neurons
and withdrawal from the brain circuitry.
4.5. Insulin/IGF Pathway. The interacting pathways of the
insulin/insulin-like growth factor (IGF) pathway, target of
rapamycin(TOR)pathway,andsirtuinfamilyareallinvolved
in regulatory networks controlling the food intake that
impact generally on longevity, and miRNAs are involved in
the regulation of each pathway. The role of miRNAs in regu-
lating these pathways and their signiﬁcance for organism
aging has been comprehensively discussed in a recent paper
by Baek et al. [25].
To summarize, the IGF and TOR pathways are conserved
and well-deﬁned regulatory signaling pathways, which play
a critical role in protein synthesis and glucose homeostasis.
Mutations that inhibit these pathways or cause expression
reduction are known to extend lifespan in C. elegans [69],
Drosophila[70],mice[8],andevenhumans[71,72],andevi-
dence from lower organisms has revealed the signiﬁcance of
miRNAs in modulating the IGF pathway. For example, it
has been reported that overexpression of miR-100 inhibits
bothmTORmRNAandproteinlevels[73].Sirtuinspromote
longevity by reducing calorie intake in yeast and mammalian
cells [74]. SIRT1 was linked to brain physiology and neu-
rological disorders. In a mouse model of Alzheimer’s disease,
the induction of SIRT1 expression improved neuronal sur-
vival and suppressed β-amyloid production [75, 76]. SIRT1
exerts the neuroprotective eﬀect by activating the retinoic
acid receptor beta that leads to induction of α-secretase
(ADAM10). ADAM10 in turn inhibits β-amyloid produc-
tion. In addition, ADAM10 activation by SIRT1 also induces
the Notch signaling pathway, which is known to repair neu-
ronal damage in the brain [76]. miR-217 is progressively in-
creased during ageing in the endothelial cells, and it can
reduce SIRT1 expression through binding to a cognate re-
sponse elements within SIRT1 3  UTR of SIRT1 [77]. miR-
34a is a downstream target of p53, and it also targets SIRT1
[56], indicating a connection between SIRT1 and the ageing
signaling pathway.
5. Concluding Remarks
The discovery of miRNAs has revealed a new layer of reg-
ulation of gene expression, and studies in recent years have
shown that miRNAs not only have a unique expression pro-
ﬁle in the brain and peripheral nervous system but also play
crucial roles in the regulation of both neuronal cell devel-
opment and function. miRNA play an important role in the
molecular control of brain development and subsequently
in the aging process and associated neuron pathologies. The
complex networks aﬀected by miRNAs and the regulatory
feedback loops are summarized in Figure 3. Even thoughCurrent Gerontology and Geriatrics Research 7
the precise situation is likely considerably more complicated,
these studies provide a new insight into how the cell regu-
latory systems, for example, interactions between miRNAs,
cell signaling, and transcription pathways, are involved in
multiple cellular activities that inﬂuence brain aging.
In this paper, we summarized the data that reveal a
new role for miRNAs in brain aging and neurodegeneration.
These studies not only demonstrate that miRNA-mediated
inhibition is important for maintaining neuron homeostasis,
but also they show that release of this inhibition can be an
important part of increased brain susceptibility to external
andinternalstressduringtheagingprocess.Proteinsynthesis
has long been identiﬁed as essential for the formation of
long-term memories, and it is therefore not entirely surpris-
ing that miRNAs are involved in this process.
T h eﬁ e l do fm i R N Aa n dn c R N Ar e s e a r c hh a sd e v e l o p e d
quickly,andwiththe identiﬁcation ofbrain-speciﬁcmiRNAs
in recent years, a new level of understanding of brain abnor-
malities associated with the aging has been acquired. How-
ever, more work remains to be done to fully understand
the miRNA mechanism of action in normal brain aging
and neurodegenerative conditions, so that expression of the
miRNAs can potentially be exploited as a new point of
entry for therapy. With the growing number of miRNAs and
ncRNAs, each carrying a long list of putative targets, the
challenge is now to annotate their biological functions.
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